EPZ-5676 treatment for lung cancer appears to be, anyway, controversial, since most of the genes involved in EMT were not found to be affected by the drug, both in the presence and the absence of TGF-β1 stimulation (Evanno et al., 2017). This evidence concerns the gene TGFB1 and lung cancer.